



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Ref. No.: PDL/RKR/Co./2018-19/200

Date: 14th November, 2018

The National Stock Exchange of India Limited
"Exchange Plaza", Banda Kurla Complex
Bandra East, Mumbai
Maharashtra
SYMBOL: PARABDRUGS

Listing Compliance Cell
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai
SCRIP Code:- 533211

SUBJECT: Unaudited Quarterly Financial Results for the Quarter and half yearly ended on 30th September, 2018 under Regulation 33 of the SEBI (LODR) Regulations, 2015

Dear Sir/ Ma'am,

Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the **Un-audited Financial Results for the Quarter and half year ended on 30th September, 2018.**

Further to note that as per the provisions of Regulation 33 (d) of the SEBI (LODR) Regulations, 2015, the listed entity is required to submit the Limited Review Report or audit report with Un-audited financial statements. However, the statutory auditor of the Company has resigned w.e.f. 1st October, 2018, and therefore Company is unable to submit the Limited review report for the quarter ended on 30th September, 2018.

The Company shall submit the limited review report as soon as new statutory auditor of the Company is appointed.

You are requested to display the same on the Notice Board of your Exchange for the information of members and general public.

Thanking You

Yours Faithfully,
For Parabolic Drugs Ltd.

Raj Kumar Ralhan



Raj Kumar Ralhan
Regn.No.: IBBI/IPA-001/IP-P00981/2017-2018/11614
Resolution Professional of Parabolic Drugs Limited
Address: Flat No. 801, Tower 01, Kalypso Court, Jaypee Greens Wish Town,
Sector 128, Noida, Uttar Pradesh, 201304
Email: rajkumarralhan@gmail.com



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Statement of Assets and Liabilities as at 30th September 2018

Rs. in Crores

Sr.no.	Particulars	As at 30/09/2018	As at 31/03/2018
		Un Audited	Audited
A	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and equipment	308.25	326.37
	(b) Capital Work in progress	6.52	6.52
	(c) Non current Investments	6.34	6.34
	(d) Other non-current assets	1.37	2.18
	Total Non-Current Assets	322.48	341.41
2	Current Assets		
	(a) Inventories	2.10	15.88
	(b) Trade Receivables	28.15	28.82
	(c) Cash and cash equivalents	0.72	0.78
	(d) Short term loans and advances	27.11	28.31
	(e) Other Current assets	3.73	3.74
	Total Current Assets	61.81	77.53
	TOTAL ASSETS	384.29	418.94
B	EQUITY & LIABILITIES		
1	Equity		
	(a) Equity Share Capital	61.89	61.89
	(b) Other Equity	(959.10)	(934.22)
	(c) Share application money pending for allotment	26.00	26.00
	Total Equity	(871.21)	(846.33)
2	Non-current liabilities		
	(a) Financial Liabilities		
	- Borrowings	831.68	836.33
	(b) Provisions	0.92	1.04
	(c) Deffered Tax Liabilities (Net)	34.21	34.70
	Total Non-current liabilities	866.81	872.07
3	Current Liabilities		
	(a) Financial Liabilities		
	- Borrowings	150.40	147.78
	- Trade Payables	68.51	80.87
	(b) Other Current Liabilities	169.78	164.55
	Total Current liabilities	388.69	393.20
	TOTAL EQUITY AND LIABILITIES	384.29	418.94

VII	Profit / (Loss) before extraordinary items and tax (V - VI)	(13.63)	(11.72)	(13.78)	(25.36)	(25.94)	(54.82)
VIII	Tax expenses:						
	(a) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred tax	0.71	(1.20)	0.45	(0.49)	0.90	1.76
IX	Net Profit / (Loss) after tax from Continuing Operations (VII-VIII)	(14.35)	(10.52)	(14.23)	(24.88)	(26.84)	(56.58)
X	Other Comprehensive Income / (Expense) (Net of Tax)	0.00	0.00	0.00	0.00	0.00	(0.42)
XI	Total Comprehensive Income / (Expense) (Net of Tax)	(14.35)	(10.52)	(14.23)	(24.88)	(26.84)	(57.00)
XII	Paid-up Equity share capital (Face value of Rs.10/- each)						
	- Issued and Subscribed Capital	61.89	61.89	61.89	61.89	61.89	61.89
XIII	Earning Per Share (EPS) (Equity shares of Rs. 10/- each fully paid up)						
	a) Basic in Rs.	(2.32)	(1.70)	(2.30)	(4.02)	(4.34)	(9.21)
	b) Diluted in Rs.	(2.32)	(1.70)	(2.30)	(4.02)	(4.34)	(9.21)

Notes :

1. The Corporate Insolvency Resolution Process ("CIRP") is initiated against Parabolic Drugs Limited ("Company") vide order dated 30th August, 2018 by NCLT, Chandigarh Bench under the Insolvency and Bankruptcy Code, 2016 ("IBC"). Pursuant to the order dated 8th October, 2018 by NCLT, Chandigarh Bench, Mr. Raj Kumar Raihan was appointed as the Resolution Professional ("RP") for the Company.

Pursuant to the provisions of IBC, as the powers of the Board of Directors have been suspended, the above results have not been adopted by the Board of Directors. However, the same has been signed by Mr. Pranay Gupta, Managing Director of the company confirming accuracy & completeness of results. These financial results have thereafter been taken on record by the RP on 14th November for filing with the stock exchanges.

2. During the period under review, the company has incurred loss owing to the unfavorable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.

3. The promoters' shareholding (22619927 Equity shares) has been pledged pursuant to the terms of CDR package.

4. There is not more than one reportable segment i.e. Pharmaceuticals business only hence information as per AS 17 is not required to be disclosed.
5. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
6. As per Ind. AS 18, Revenue for the quarter ended 30th September, 2018 is reported net of duties.
7. M/s J.M. Financial Asset Reconstruction Company Private Limited has already taken over the Loans/Debts of ICICI, UCO, IDBI & SBI. However the balance with M/s J M Financial Asset Reconstruction Company Private Limited is subject to confirmation & Reconciliation as on 30.09.2018
8. The balance in Loan accounts with SIDBI, Union Bank of India, EXIM Bank and Central Bank of India Cash Credit Account is subject to confirmation & Reconciliation as on 30.09.2018
9. Tax Expenses includes Income Tax & deferred Tax liability (Net).
10. As per the provisions of Regulation 33 (d) of the SEBI (LODR) Regulations, 2015, the listed entity is required to submit the Limited Review Report or audit report with Un-audited financial statements. However, the statutory auditor of the Company has resigned w.e.f 1st October, 2018, and therefore Company is unable to submit the Limited review report for the quarter ended on 30th September, 2018.

For Parabolic Drugs Limited

Pranav Gupta

Managing Director (DIN: 00914361)

Taken on Record

Raj Kumar Ralhan
(Resolution Professional)

Regn.No.: IBBI/IPA-001/IP-P00981/2017-2018/11614

Place : Chandigarh
Date : 14th November 2018